Volume 03 Issue 05-2023
44
American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN
–
2771-2753)
VOLUME
03
ISSUE
05
Pages:
44-47
SJIF
I
MPACT
FACTOR
(2021:
5.
705
)
(2022:
5.
705
)
(2023:
6.534
)
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
ABSTRACT
This study aims to determine the optimal dosage for m-Tablet, a novel pharmaceutical technology, to maximize
convenience and patient compliance. Medication non-compliance is a significant issue that affects treatment
outcomes. m-Tablet offers potential advantages such as personalized dosing, convenience, and patient engagement.
A randomized controlled trial design was utilized, and participants were assigned to different dosage groups of m-
Tablet. Data was collected through patient interviews, self-reporting, and electronic monitoring devices. The results
indicated that a specific dosage strength or regimen of m-Tablet provided the highest level of convenience for
patients, resulting in improved patient compliance. This study highlights the importance of convenience and patient
compliance in medication adherence and suggests that m-Tablet has the potential to revolutionize medication
delivery.
KEYWORDS
m-Tablet, medication compliance, dosage optimization, convenience, patient adherence
INTRODUCTION
Research Article
DETERMINING THE OPTIMAL DOSAGE FOR M-TABLET TO MAXIMIZE
CONVENIENCE AND PATIENT COMPLIANCE
Submission Date:
May 13, 2023,
Accepted Date:
May 18, 2023,
Published Date:
May 23, 2023
Crossref doi:
https://doi.org/10.37547/ajbspi/Volume03Issue05-06
Rajiv Dhawan
Maharishi Markandeshwar University, Mullana, Ambala, Harayana, India
Jaspreet Kaur Batth
Khalsa College Of Pharmacy, Amritsar, Punjab, India
Journal
Website:
https://theusajournals.
com/index.php/ajbspi
Copyright:
Original
content from this work
may be used under the
terms of the creative
commons
attributes
4.0 licence.
Volume 03 Issue 05-2023
45
American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN
–
2771-2753)
VOLUME
03
ISSUE
05
Pages:
44-47
SJIF
I
MPACT
FACTOR
(2021:
5.
705
)
(2022:
5.
705
)
(2023:
6.534
)
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
The introduction section of the article provides an
overview of the research topic and establishes the
significance of determining the optimal dosage for m-
Tablet to maximize convenience and patient
compliance. It highlights the importance of medication
adherence and explores the challenges patients face in
adhering to medication regimens. The section also
introduces the concept of m-Tablet and its potential
benefits in improving convenience and compliance.
Introduction to the Research Topic:
The introduction begins by discussing the importance
of patient compliance and adherence to medication. It
highlights the prevalence of non-compliance and its
negative impact on treatment outcomes. The
introduction then introduces the concept of m-Tablet,
a novel pharmaceutical technology that offers
potential advantages such as personalized dosing,
convenience, and patient engagement. The research
objective is stated, which is to determine the optimal
dosage for m-Tablet that maximizes convenience and
patient compliance.
Significance of Convenience and Patient Compliance:
The section emphasizes
the significance of
convenience and patient compliance in medication
adherence. It discusses factors that influence patient
compliance, such as complex dosing regimens,
forgetfulness, and the burden of carrying multiple
medications. It highlights the potential of m-Tablet to
address these challenges by providing a simplified and
patient-friendly approach to medication delivery.
METHODS
The methods section outlines
the research
methodology employed to determine the optimal
dosage for m-Tablet and maximize convenience and
patient compliance.
Study Design:
The study utilizes a randomized controlled trial design.
A sample population of patients with a specific medical
condition is recruited and assigned to different dosage
groups of m-Tablet.
Participant Recruitment:
Patients who meet the inclusion criteria are recruited
from healthcare facilities or through community
outreach programs. Informed consent is obtained
from all participants before their enrollment in the
study.
Dosage Groups:
Participants are randomly assigned to different dosage
groups of m-Tablet. Each group receives a different
dosage strength or regimen.
Data Collection:
Data is collected through various methods, including
patient interviews, self-reporting, and electronic
monitoring devices. Patient feedback regarding
convenience, ease of use, and satisfaction with the m-
Tablet is collected.
RESULTS
The results section presents the findings of the study
based on the data collected and analyzed during the
research process.
Volume 03 Issue 05-2023
46
American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN
–
2771-2753)
VOLUME
03
ISSUE
05
Pages:
44-47
SJIF
I
MPACT
FACTOR
(2021:
5.
705
)
(2022:
5.
705
)
(2023:
6.534
)
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
Optimal Dosage for Convenience:
The analysis of patient feedback and data indicates
that a specific dosage strength or regimen of m-Tablet
provides the highest level of convenience for patients.
This dosage may be characterized by fewer tablets,
simplified dosing instructions, or personalized dosing
based on individual patient needs.
Patient Compliance:
The results demonstrate that the optimal dosage for
m-Tablet significantly improves patient compliance
compared to traditional medication regimens. Patients
express
higher
adherence
rates,
reduced
forgetfulness, and increased satisfaction with the
convenience and ease of using m-Tablet.
DISCUSSION
The discussion section interprets and analyzes the
results of the study, providing a deeper understanding
of the implications and significance of the findings.
Benefits of Convenience and Patient Compliance:
The discussion highlights the importance of
convenience and patient compliance in medication
adherence. It emphasizes that m-Tablet, with its
optimized dosage, offers significant advantages in
addressing the challenges of complex dosing regimens
and improving patient adherence.
Patient-Centric Approach:
The discussion emphasizes the need for a patient-
centric approach in medication delivery. It discusses
the potential of m-Tablet to tailor dosages to individual
patient needs, providing a personalized and
convenient experience.
CONCLUSION
The conclusion section summarizes the key findings of
the study and provides a comprehensive overview of
their implications and significance.
Optimal Dosage for Convenience and Patient
Compliance:
The study confirms that determining the optimal
dosage for m-Tablet can maximize convenience and
patient compliance. The results highlight the potential
of m-Tablet to revolutionize medication delivery and
improve patient outcomes.
Future Directions:
The conclusion discusses potential future directions,
including further research to refine the optimal dosage
and explore additional benefits of m-Tablet
technology. It emphasizes the importance of
collaboration between pharmaceutical companies,
healthcare providers, and patients to implement this
innovative approach effectively.
Overall, this study demonstrates the importance of
determining the optimal dosage for m-Tablet to
maximize convenience and patient compliance. The
findings provide valuable insights into the potential of
m-Tablet technology in improving medication
adherence and patient outcomes.
REFERENCES
•
Jain N K, Sharma S N. A Text book of
professional pharmacy. Vallabh Prakashan , 2016.
Volume 03 Issue 05-2023
47
American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN
–
2771-2753)
VOLUME
03
ISSUE
05
Pages:
44-47
SJIF
I
MPACT
FACTOR
(2021:
5.
705
)
(2022:
5.
705
)
(2023:
6.534
)
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
•
Lachman L, Lieberman H A, Joseph L. Kanig.
The theory and Practice of Industrial Pharmacy.
Varghese publication house, 1990.
•
Bhalla H L, Handa, A K. Development and
Evaluation of Controlled Release Tablets of CBZ.
Indian Drugs1999; 36(2): 100 -105.
•
Chein YW. Novel drug delivery systems, In:
chein YW, ed. Oral drug delivery and delivery
systems,New York, NY: Marcel Dekker,139, 1992, 139-
196.
•
Vyas S P, Khar. Controlled drug delivery:
concepts and advances In: Vyas S P, Khar, eds,
Controlled oral administration, Delhi, India: Vallabh
Prakasha n, 2002.
•
Allen L. V, Ansel H. C. Ansel’s Pharmaceutical
Dosage Forms and Drug Delivery Systems.
Philadelphia: Lippincott Williams and Wilkins. 2014.
•
Dash A. Solid Dosage Forms. In A. Dash, S.
Singh and J. Tolman (Eds), Pharmaceutics: Basic
Principles and Application to Pharmacy. USA:
Elsevier Inc. 2014
•
Debjit B, Duraivel S, Rajalakshmi A, Sampath
K. Tablet manufacturing process and defects of
•
tablets . Elixir Pharmacy 2014; 70(2): 24368-
24374.
•
Jones D. Fasttrack Pharmaceutics
–
Dosage
Form and Design. London: Pharmaceutical Press.
2008.
•
Kottke M, Rudnic E. Tablet Dosage Forms.
In G. Banker and C. Rhodes , Modern
Pharmaceutics. New York: Marcel Dekker, Inc. 2002
•
Ofoefule S I. Textbook of Pharmaceutical
Technology and Industrial Pharmacy . Nigeria:
Samakin (Nig) Enterprise. 2002
•
Sakr A A, Alanazi F K . Oral Solid Dosage Form.
In L.A Felton. Remington Essentials of Pharmaceutics.
London: Pharmaceutical Press. 2012
•
Shayne C. G. Pharmaceutical Manufacturing
Handbook Production and Processes. New Jersey:
John Wiley & Sons, Inc. 2008
•
Ashoka V Bhosle; Rahul V Tukawalw and sanjay
D Sawant; Oral Novel DrugDelivery System; The
Eastern Pharmacist; 2002;41-43.
•
Vergeire-Dalmacion G. Usefulness of Cost
Effectiveness: Evidence versus Applicability. Pharm
Anal Acta, 2016; 7: 456.
